Data show that simufilam reduced seizure activity in a preclinical mouse model
Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program
June 30, 2025 -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that the Company presented a poster at the TSC International Research Conference (TSC 2025